Shine On You Crazy ...
Health Care: Drugs
Merck & Co Inc (MRK: NYSE)
$45.99 0.78 | 1.73%
05/21/13 - 01:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | 6.30B | 6.39B | 982.00M | 13.02B |
| Operating Gains/Losses | -351.00M | -530.00M | -706.00M | -11.74B |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 349.00M | -1.17B | -1.09B | 165.20M |
| (Increase) Decrease in Inventories | -482.00M | -678.00M | 1.99B | 1.21B |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -302.00M | 182.00M | 124.00M | -45.20M |
| (Decrease) Increase In Other Current Liabilities | -751.00M | 1.17B | 163.00M | -4.37B |
| (Increase) Decrease In Other Working Capital | -2.95B | -269.00M | -258.00M | 330.10M |
| Other Non-Cash Items | 563.00M | 1.40B | 3.33B | 415.50M |
| Net Cash From Continuing Operations | 10.02B | 12.38B | 10.82B | 3.39B |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 10.02B | 12.38B | 10.82B | 3.39B |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -1.95B | -1.72B | -1.68B | -1.46B |
| Acquisitions | 0.00 | -50.00M | 391.00M | -8.97B |
| Purchases of Short-Term Investments | -12.84B | -7.32B | -7.20B | 0.00 |
| Other Cash from Investing Activities | 207.00M | -116.00M | 426.00M | 5.72B |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -6.80B | -2.89B | -3.50B | 3.16B |
| Issuance of Debt | 2.56B | 0.00 | 2.00B | 4.23B |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 1.31B | 321.00M | 363.00M | 186.40M |
| Repayment of Long-Term Debt | -22.00M | -1.55B | -1.34B | -2.45B |
| Repurchase of Capital Stock | -2.59B | -1.92B | -1.59B | 0.00 |
| Payment of Cash Dividends | -5.24B | -4.81B | -4.85B | -3.48B |
| Other Financing Charges, Net | 710.00M | 1.05B | -16.00M | -126.30M |
| Net Cash From Financing Activities | -3.27B | -6.90B | -5.44B | -1.64B |
| Effect of Exchange Rate Changes | -30.00M | 42.00M | -295.00M | 33.40M |
| Net Change in Cash & Cash Equivalents | -80.00M | 2.63B | 1.59B | 4.94B |
Portfolios with MRK
- Portfolio NameUser Type
- User2013
- ContributorStocks Rising On Unusual Vo...
- UserJeeper Portfolio 1
- UserCapt Jer
- Userlennyvb Portfolio 1
- ContributorDogs of the Dow 2013
- ContributorTechnical Setups for the We...
- ContributorHigh Volume Technicals for ...
- UserCovered Calls
- Contributor9 Dow Dividend Stocks With ...
Latest MRK Headlines from TheStreet
- Dow Today: Merck (MRK) Higher 05.21.13 | 12:05 pm
- Cramer's 'Mad Money' Recap: Think Dividends, Not Coupons 05.20.13 | 08:05 pm
- Dow Today: Merck (MRK) Lower 05.17.13 | 12:05 pm
- ASCO '13 Preview: New 'Anti-PD-1' Therapies Shrink Tumors 05.15.13 | 06:05 pm
- 5 Stocks Boosting The Drugs Industry Higher 05.15.13 | 01:05 pm
- What's Missing in the Market; 3 Short Ideas That Don't Work: Cramer's Best Blogs 05.11.13 | 04:05 pm
- Merck & Co Inc (MRK): Today's Featured Drugs Winner 05.09.13 | 05:05 pm
- Biotech's Next Big Thing: ASCO
05.09.13 | 09:05 am - 5 Stocks Advancing The Drugs Industry 05.07.13 | 01:05 pm
- It's Pipeline That Matters Most 05.04.13 | 04:05 am
Press Releases for MRK
- Sanford Heisler Files $100m+ Discrimination Suit Against Pharma Giant Merck & Co., Inc. - PR Newswire 05.09.13 | 09:05 am
- Merck And Celebrity Chef Art Smith "Cook Up A Recipe" For Better Type 2 Diabetes Management - PR Newswire 05.07.13 | 08:05 am
- Merck Consumer Care Launches Health And Wellness Effort To Help Empower Moms To Live A More Active Lifestyle With Their Families - PR Newswire 05.06.13 | 09:05 am
- Pharmaceutical Companies, Investor Coalition Develop Industry Standard-Setting Principles For Recoupment Policies Covering Major Compliance Failures - PR Newswire 04.04.13 | 08:04 am
- Merck Announces FDA Acceptance Of Biologics License Application For Investigational Grass Pollen Allergy Immunotherapy Tablet - Business Wire 03.27.13 | 08:03 am
- Merck And Luminex Corporation Enter Agreement To Develop Companion Diagnostic To Support Investigational BACE Inhibitor Clinical Development Program For Alzheimer’s Disease - Business Wire 03.13.13 | 08:03 am
- Results From HPS2-THRIVE Study Of TREDAPTIVE™ (extended-release Niacin/laropiprant) Presented At American College Of Cardiology Scientific Sessions - Business Wire 03.09.13 | 12:03 pm
- Roger M. Perlmutter (Photo: Business Wire) - Business Wire 03.07.13 | 07:03 am
- Merck To Present At The 33rd Annual Cowen Health Care Conference - Business Wire 03.05.13 | 08:03 am
- Merck Announces Second-Quarter 2013 Dividend - Business Wire 02.26.13 | 02:02 pm
Partner Headlines for MRK
- Companies slide $181B through tax loopholes - MSN Money 04.19.13 | 10:04 am
- Revive leadership in pharma R&D - Financial Times 04.17.13 | 08:04 pm
- Market Close Report: NASDAQ Composite index closes at 3,297.25 up 59.39 points - NASDAQ 04.10.13 | 08:04 pm
- Market Close Report: NASDAQ Composite index closes at 3,218.60 down -36.26 points - NASDAQ 04.03.13 | 08:04 pm
- 10 Sharp Healthcare Dogs Diagnose 7.4% To 62.1% Gains In March - Seeking Alpha 04.01.13 | 09:04 am
- New foot-and-mouth vaccine developed - Financial Times 03.27.13 | 11:03 pm
- 'Pay For Delay' Case Could Change Generic Drug Rules - Investor's Business Daily 03.26.13 | 04:03 pm
- Common Sense Says Time For Quality, Dividends And Premiums - Seeking Alpha 03.23.13 | 06:03 am
- Top 9 March Healthcare Dogs Mark 3.4% To 28.7% Gains - Seeking Alpha 03.23.13 | 04:03 am
- Looking For Bargains And Safety - Seeking Alpha 03.17.13 | 09:03 am
